{"name":"MediLink Therapeutics (Suzhou) Co., Ltd.","slug":"medilink-therapeutics-suzhou-co-ltd","ticker":"","exchange":"","domain":"medilinksuzhou.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"YL202","genericName":"YL202","slug":"yl202","indication":"Type 2 diabetes","status":"phase_3"},{"name":"YL201","genericName":"YL201","slug":"yl201","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"YL201 and atezolizumab","genericName":"YL201 and atezolizumab","slug":"yl201-and-atezolizumab","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"YL202","genericName":"YL202","slug":"yl202","phase":"phase_3","mechanism":"YL202 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"YL201","genericName":"YL201","slug":"yl201","phase":"phase_3","mechanism":"YL201 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"YL201 and atezolizumab","genericName":"YL201 and atezolizumab","slug":"yl201-and-atezolizumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOeFJRTUpXdkVMSm1MS1ZRUER3dkVXM0h3ajhVNG9qS0UtSktuQkMzVTQ1RWFiLUx5ckQyeExGREY5NHVNRDNMR2I3WjBpcThiT3RvRDNqeVVxTVJiOXBIdWZvcHlnSnNldkd6OVoySzlhblhTQk5mMUZ3TXVTcTJDX3JnblJESVM5alJkMl9DSm5kZ1VQMFM2ZFprUnFXVGxfbmdMdk81aHloRlgtN0F0Y3ZxZVpxOGhNQUhfeVBneHgyNF9ZeldDNTA1TlZVaEg3amM0d0JGb1o?oc=5","date":"2026-03-17","type":"deal","source":"Citeline News & Insights","summary":"Pfizer, Roche Looking Beyond Simple Licensing In China Deals - Citeline News & Insights","headline":"Pfizer, Roche Looking Beyond Simple Licensing In China Deals - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOM21NWGJUU3VHRnF1NzFjNk1RelV4RGVxWXVYN19jNGhVNjZIekt5YktjYTRBejRQeGE2VWd6V0RESG92eldPZms4RDlFZ0kxWmdtb0Z2ODFtR1ZTQWJCM0Nha0p4YXhoazJrdV9rYzVUVDlxTnAyVXRMOTdkeTR1S3ZyMDJ3TW4xU3lQa0pNY1dzeGt1R0E4Xy14bFlISWJkck1WRUdDMTFzOW5YOWlHalB5ZmpZcWR2dGxNNTEzbGhyUklaZWtWMG9fTWU1NGtPRWRIS3AyanphRFhaYmQtTGRIX21YNkRKYS1aUDNRbFFjWnN3Ti1GX3JOc3Y?oc=5","date":"2024-10-17","type":"pipeline","source":"PR Newswire","summary":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight - PR Newswire","headline":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPUVhVZzRrX0pVajNaREFhR21pY19xS1dIcmh0WGFOQTQ2ZWNXX291UmFpZlBCZ21wVGZ2WVpCcko4Qmh1S0lpeDJ1dFRCOFd1azl2VTFFLWswRE9sUTNyd3FZNWlCWEJGMDUycW5abDM3WTRrWjJhWnZ3V09pZVhmeERKSkJJb3FEOUtSWHRpakR2M2k2RVpYQVhRX3JXeVZKbDVtd2hlNkxvYWlxVEd5aUlFZUJYTmtXU25QYnowT1d2TnI1QnN5WVo2akVwMnRJRFdvU2FkWmRScmhDLVFQbWFGWkJkVWdtSFI0VGNUMktjbVM5ZHJwM0JuaTZmN3FVZ3Y4SG90VVQzUVRDUUY3bmtSRG91NElO?oc=5","date":"2024-10-08","type":"deal","source":"BioPharma APAC","summary":"MediLink Therapeutics and Amgen Announce Global Clinical Collaboration to Evaluate Combination Therapy for Extensive-Stage Small Cell Lung Cancer - BioPharma APAC","headline":"MediLink Therapeutics and Amgen Announce Global Clinical Collaboration to Evaluate Combination Therapy for Extensive-Sta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQMHF1c0JaUWJ4TnN4TlZCcm9RXzhhNzdHUXdQdVB6bHAzQ0hsdkY1eXhlYkoxd1B0NXlmTW1BVXB4UzR3Q3BhVmY1TE54WjRvUEM5RWdSd2d5cnNEQ0R0VVNpMEd5MkpGdkJKZEVNRFEyRXNWUVhYNFVCc2NWZG1OTkY1ZVpFcC1YbkxURlExaW9SNkNMNi1INmh4QWtsY2Nx?oc=5","date":"2024-08-19","type":"regulatory","source":"Contract Pharma","summary":"FDA Lifts Hold on MediLink’s BNT326/YL202 Phase I Trial - Contract Pharma","headline":"FDA Lifts Hold on MediLink’s BNT326/YL202 Phase I Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQTkgtTUV5clJfWGNrUGFkY0VhX1h2Z3h2VE5XQVlnbkdSVDFUMDk2aFVzWDk4ZHZtVGtLS29ueUpWSzJkZGhGZzJQQWIzTXpoTWx2dTR1M1JiQUQ0Ml9zcHN5WUd4Qi1ZNkdVdExYaVBla1RObVN0YWUyR1VUMFFLN1FiSElUOG5xWlBnNS01cmNwUlQwVGlFRTFn?oc=5","date":"2024-07-11","type":"pipeline","source":"DCAT Value Chain Insights","summary":"The CDMO/CMO Report: Strong Growth Drives Contract ADC Market - DCAT Value Chain Insights","headline":"The CDMO/CMO Report: Strong Growth Drives Contract ADC Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOMTBycmFDa3VYTWMxaWRmNE5qZTV4YWQzcnh2NHRmVW5kRm44WjhnRk84WnR6QXNIOWk3SG40UTNKbmtyRU1lMTlxTlVILWxOdUQ4UlZDcUlpb01OVVZROXdPaGQ3TmlCUEhrRlFCVk9yaUJWYzlFa3FqaVhnNlVuMndUdUgyWHlxR09zaC1KdjlockNPUmRVczQ5dkNsQ3dTZDFKSg?oc=5","date":"2024-01-09","type":"deal","source":"BioWorld News","summary":"Argo, Novartis sign two deals for CV assets for potentially $4B+ - BioWorld News","headline":"Argo, Novartis sign two deals for CV assets for potentially $4B+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNMVJlSVM1Q1BfaEZKaWtxX0RQWXZSd1VmTmFISUNUd1dCTXhLeTFjTW1zdi1HR1pkTEJQRXZCMlhIVVdzbGM4V2F6d2QtbDJZZGxxbExXaW01Sm9wSUE2b3BBZjZLdGJlRXdpY2d1NnBuR2llOGpkemh2UEM0UkZ1QnRyNHBycDNTMk0zWUhRVDFPUlRvUkNkV01tTkNVRHZPTV9HeldTa1lYTm5iTnZuRUpVQzZpcFN3b3NRaEd3N3lTeXZhV1IxNVpXUE54WW9vUEYxM09CdXE1YXh4amVuYU0tamFEZlNJQXlyLTJzai1SRzlWc1VPeGUtdGtRMnpsc0VTMy1vdW9HQ1A3Z2p3OXROWklELXBYZE52bUdqMS1DbGJ6MXJ6YUdTVjMzUVlH?oc=5","date":"2024-01-02","type":"deal","source":"PR Newswire","summary":"MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology - PR Newswire","headline":"MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation anti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxOdGZObEtCX3RONWZKUUhmUVNQbm4tTDJzbmRiN0pqamlLZ2E0SmlOS0QybXB2ZEdLUG1kZGdkdHpwaHlSU3FSR0Q1RkVmbEtpdFpHaXh5Ylp4VUstNHVTVldFcnpBbnNHd0hwaTUtTi1HYzBkblF3RnUwNTZ6dHJDSVM2TmJINGxWTHJObGJza2xrUWxRcEpOV0hzMlRTUTgyaFZ4Tmd0cXRiNTg5RmktN1d2enp2ZUdvdTI0ZHRpUUhtWk1BOEdLX3pjNndTcDMybmt5d19QSVhJX2dtc3pjdjhHWWxnWE15WkNTU2Y5a3B4VWxJTnBMOGtoeWlPbVl0RzZzcmpudE91aXZnOEdVMDRQWi1xdHBnY2VXU3NMZ3dVc0lWUFA2MGxaYjUyYUtfLUYxRnZaeE1WYWs4eTMyak9n?oc=5","date":"2023-10-12","type":"deal","source":"PR Newswire","summary":"MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate - PR Newswire","headline":"MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-ge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNUHNmZHRuLUxtN24zcUhRZlVBTUY0NmYzQjA4RV9tX2YzQS1yQ2gtQ0tOMmRPTUlUVTlUUGt5ajhTUVk3dGQ0UlA0V2YyREFHZE43QUpEZVZPeFQtMGpkbU0xaS1ibFdGQXE0U3hjbFlLR1p2NEhuaWg1b3NuVlZaSmE5ZGlTeTJIbVIxTXBlUl9qMmFpZWszWDFGeDdHT1R3NTJhcUd4UXVWTGhNNmRoaW54Y2FzSjA?oc=5","date":"2022-03-14","type":"pipeline","source":"PR Newswire","summary":"MediLink Therapeutics closes US$70 million Series B financing - PR Newswire","headline":"MediLink Therapeutics closes US$70 million Series B financing","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}